Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot -

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-06

Study Completion Date

2021-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect with the vast majority of survivors of corrective surgery left with some degree of right ventricular (RV) volume overload due to pulmonary regurgitation (PR) which cause RV enlargement with right heart failure, diminished biventricular function, ventricular arrhythmia, sudden death and decreased exercise performance over time. Pulmonary valve replacement (PVR) has been thought to ameliorate these complications but the timing of replacement has yet to be determined with equipoise at the moment in this decision making process. As nearly all studies in this regard are retrospective with much less data in pediatric TOF than adults, this pilot trial sets the stage to create a prospective randomized trial in the teenage years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Two Pulmonary Valve Replacement Methods to Treat Tetralogy of Fallot

NCT00112320

Tetralogy of Fallot Pulmonary Valve Insufficiency Ventricular Dysfunction, Right

COMPLETED NA

Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction

NCT03441971

Heart Defects, Congenital Tetralogy of Fallot Pulmonary Valve Insufficiency +1 more

ACTIVE_NOT_RECRUITING NA

Partial Heart Transplantation

NCT06055556

Congenital Heart Disease

WITHDRAWN NA

New Designed ePTFE Valved Conduits for Surgical Reconstruction of Right-ventricular Outflow Tract

NCT04152967

Right Ventricular Outflow Tract Absent Congenital Heart Disease Pulmonary Valve Disorders

UNKNOWN NA

NHLBI and Cook Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA) Early Feasibility Study

NCT06479824

Tricuspid Valve Insufficiency

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this research study is to gather information on adolescents and young adults to help understand and improve the lives of patients with TOF.

Some patients diagnosed with TOF will have a procedure called pulmonary valve replacement (PVR) and some will not. PVR is done for valves that are too damaged to be repaired. This requires a surgeon or an expert in a procedure called cardiac catheterization to replace the damaged pulmonary valve with a valve made of tissue or a mechanical valve. Multiple studies in adult TOF patients have suggested that PVR may lessen many clinical symptoms but no one is sure if it truly does. There is little information about PVR in adolescence but it is thought that lessening the amount of leakage of the pulmonary valve at a young age may avoid future complications such as right heart failure or abnormal beats of your heart. There is no agreement among cardiologists, surgeons or other healthcare providers as to whether PVR truly helps avoid complications in the future and if it does, when PVR should be done. Using the information in this study, we hope to find out if PVR in adolescents is helpful in both the short and long term.

The Investigators believe the results of this study will help provide doctors with enough information to support a future large scale research study to further evaluate the outcomes PVR. This study will involve randomization to either the PVR or no PVR cohort, medical records review, exercise test and Cardiac Magnetic Resonance (CMR) , and questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tetralogy of Fallot

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects will be randomized to PVR or no PVR

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Subjects will be randomly assigned to one of two groups. One will undergo PVR with catheter or surgery (whichever is most appropriate ). The other group will continue with medical management.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PVR Arm

PVR arm will undergo PVR via catheter or surgery

Group Type OTHER

PVR

Intervention Type PROCEDURE

Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve

No PVR

No PVR group will continue with medical management

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PVR

Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females with repaired Tetralogy of Fallot (TOF), currently between 13 and 21 years of age.
2. On clinical Cardiac Magnetic Resonance (CMR) : Right Ventricular End-Diastolic Volume Index (RVEDVi) between 140 and 180 cc/m2 inclusive with Right Ventricular End-Diastolic Function (RVEF) \> 40% and Left Right Ventricular End-Diastolic (LVEF ) \> 50%, RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped); there will be no indexed Right Ventricular end-systolic volume (RVESVi) criteria; by defining RVEDVi and RVEF, Investigators will be inherently defining RVESVi
3. On clinical echocardiogram: RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped), at least mild pulmonary insufficiency and tricuspid regurgitation with an RV pressure estimate \< 1/2 systemic pressure.
4. On Exercise Stress Test (EST), aerobic capacity \> 60% of predicted.
5. No Q-wave, R-wave, S-wave (QRS) duration criteria on ECG.

Exclusion Criteria

1. Any condition judged by the patient's physician that would cause this trial to be detrimental to the patient.
2. Specific forms of TOF excluded are those with endocardial cushion defects, TOF with absent pulmonary valve and TOF with multiple aorto-pulmonary collaterals requiring unifocalization.
3. Unilateral branch pulmonary artery stenosis (one lung receives \< 25% of total flow)
4. Contraindication to non-sedated exercise CMR (e.g. pacemaker/implanted cardioverter defibrillator); need for sedation
5. If data available, moderate or greater tricuspid regurgitation on echocardiogram or CMR or Qp/Qs \> 1.5
6. Significant strokes/hemiplegia or inability to exercise
7. Genetic syndrome/developmental delay which would make QOL and EST date uninterpretable
8. Pregnancy
9. Previous pulmonary valve replacement (PVR)

Minimum Eligible Age

13 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No